These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33385274)

  • 1. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.
    Kato M; Hirakawa A; Sato H; Hanazawa R; Naito Y; Tochigi K; Sano T; Ishida S; Funahashi Y; Fujita T; Matsukawa Y; Hattori R; Tsuzuki T
    Int J Clin Oncol; 2021 Apr; 26(4):764-769. PubMed ID: 33385274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
    Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
    Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Sano T; Kimura T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Yamamoto T; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2019 Jul; 79(10):1065-1070. PubMed ID: 31025722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
    van der Slot MA; Seyrek N; Kweldam CF; den Bakker MA; Busstra MB; Gan M; Klaver S; Rietbergen JBW; van Leenders GJLH
    World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.
    Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Roobol MJ; Helleman J; van Leenders GJLH
    Histopathology; 2020 Apr; 76(5):755-762. PubMed ID: 31944367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
    Iakymenko OA; Lugo I; Briski LM; Nemov I; Punnen S; Kwon D; Pollack A; Stoyanova R; Parekh DJ; Jorda M; Gonzalgo ML; Kryvenko ON
    Prostate; 2021 Sep; 81(12):866-873. PubMed ID: 34184782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers.
    Kryvenko ON; Epstein JI; Merhe A; Iakymenko OA; De Almeida E Silva Junior R; Chanamolu DK; Briski LM; Kwon D; Nemov I; Punnen S; Pollack A; Stoyanova R; Parekh DJ; Jorda M; Gonzalgo ML
    Am J Clin Pathol; 2024 Jul; 162(1):51-61. PubMed ID: 38412318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
    van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.
    Diolombi ML; Epstein JI
    BJU Int; 2017 Jun; 119(6):872-878. PubMed ID: 27496532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
    Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
    Shah RB; Nguyen JK; Przybycin CG; Reynolds JP; Cox R; Myles J; Klein E; McKenney JK
    Histopathology; 2019 Sep; 75(3):346-353. PubMed ID: 31012493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
    J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
    Waisman Malaret AJ; Chang P; Zhu K; Zheng Y; Newcomb LF; Liu M; McKenney JK; Brooks JD; Carroll P; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Lin DW; Wagner AA
    J Urol; 2022 Apr; 207(4):805-813. PubMed ID: 34854745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Gleason pattern 4 in radical prostatectomy specimens in current practice - Quantification, morphology and concordance with biopsy.
    de Souza MF; de Azevedo Araujo ALC; da Silva MT; Athanazio DA
    Ann Diagn Pathol; 2018 Jun; 34():13-17. PubMed ID: 29661718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
    Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
    Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
    Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
    Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
    Epstein JI; Amin MB; Fine SW; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong Q; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Trpkov K
    Arch Pathol Lab Med; 2021 Apr; 145(4):461-493. PubMed ID: 32589068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification.
    Greenland NY; Cooperberg MR; Carroll PR; Cowan JE; Simko JP; Stohr BA; Chan E
    Prostate; 2024 Aug; 84(11):1076-1085. PubMed ID: 38734990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
    Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
    Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.